Causes and Clinical Impact of Elevated Ammonia

Etiology of Hyperammonemia

• Elevated ammonia arises from (1) primary deficiencies of urea‑cycle enzymes, (2) secondary inhibition of the urea cycle by metabolic disorders or drugs such as valproic acid, and (3) impaired ammonia metabolism or excretion due to acute liver or kidney dysfunction. 1, 2
• Valproic acid is the medication most frequently implicated in drug‑induced hyperammonemia through secondary inhibition of the urea cycle. 3, 1
• Organic acidemias (including methylmalonic, propionic, isovaleric, and multiple carboxylase deficiency) cause mild‑to‑moderate hyperammonemia by competitively inhibiting N‑acetylglutamate synthase. 3, 1

Primary Urea‑Cycle Disorders (UCDs)

• Congenital deficiency of any of the six urea‑cycle enzymes produces primary hyperammonemia and is a key differential diagnosis in pediatric patients. 2, 4
• Ornithine transcarbamylase (OTC) deficiency is the most common UCD, with an incidence of approximately 1 in 56,500 births. 1, 4
• Overall, UCDs occur in roughly 1 in 35,000 births. 1, 4
• Each enzyme deficiency leads to ammonia accumulation together with a characteristic pattern of substrate buildup specific to the affected step. 2

Secondary Metabolic Causes

• Organic acidemias collectively affect about 1 in 21,000 births and typically generate less severe hyperammonemia than primary UCDs. 3, 1

Organ‑Related Impairments

• Acute liver injury or failure compromises ammonia metabolism because the liver is the principal site for conversion of ammonia to urea. 3, 2, 4
• Acute kidney injury contributes to ammonia accumulation by reducing renal excretion; normally, ammonia is eliminated as urea or converted to glutamine for urinary excretion. 3, 1, 2

Age‑Specific Presentations

• Transient hyperammonemia of the newborn occurs in preterm infants, is characterized by normal urea‑cycle enzyme activity and absence of organic acidurias, and resolves spontaneously without specific therapy. 1, 4, 5
• Early‑onset hyperammonemia appears in neonates within the first few days after feeding begins, when reliance on maternal placental ammonia transport ceases. 1, 4

Clinical Significance and Pathophysiology

• Plasma ammonia concentrations exceeding 200 µmol/L are linked to poor neurological outcomes, including cerebral edema, neuronal injury, coma, and death if not promptly treated. 1, 2, 6
• Rapid elevation of brain ammonia triggers extracellular potassium rise, glutamine accumulation in astrocytes, increased intracellular osmolality, and release of inflammatory cytokines, all contributing to neurotoxicity. 3, 4, 7

Evidence‑Based Guidance on Non‑Hepatic Hyperammonemia

Primary Urea Cycle Disorders (UCDs)

• Congenital deficiency of any of the six urea‑cycle enzymes (NAGS, CPS1, OTC, ASS, ASL, ARG1) leads to primary hyperammonemia by causing ammonia accumulation and substrate‑specific metabolic patterns. [8][9]
• Ornithine transcarbamylase (OTC) deficiency is the most frequent UCD, with an incidence of roughly 1 in 56,500 births; overall UCDs affect about 1 in 35,000 births. 9

Secondary Metabolic Causes

• Organic acidemias (e.g., methylmalonic, propionic, isovaleric, multiple carboxylase deficiency) produce mild‑to‑moderate hyperammonemia through competitive inhibition of N‑acetylglutamate synthase; incidence is approximately 1 in 21,000 births. [8][9]

Drug‑Induced Hyperammonemia

• In patients receiving valproic acid who develop altered mental status, hyperammonemia should be considered even when liver disease is absent. [8][9]

Organ‑Dysfunction‑Related Causes

• Acute kidney injury reduces renal excretion of urea and glutamine, contributing to systemic ammonia accumulation. [8][9]
• Acute non‑cirrhotic liver injury or failure impairs the liver’s central role in converting ammonia to urea, thereby increasing ammonia levels. [8][9]

Age‑Specific Causes

• Transient hyperammonemia of the newborn occurs in preterm infants with normal urea‑cycle enzyme activity and resolves without targeted therapy. 9
• Early‑onset neonatal hyperammonemia appears within the first few days after feeding begins, suggesting an inherited metabolic disorder rather than a transient phenomenon. 9

Diagnostic Thresholds and Definitions

• Ammonia concentrations > 200 µmol/L are linked to severe neurological complications (cerebral edema, neuronal injury, coma, death) if untreated. 9
• Hyperammonemia is defined as > 100 µmol/L in neonates and ≥ 50 µmol/L in term infants, children, and adolescents, acknowledging laboratory‑specific reference ranges. 9

Clinical Recommendations

• When a cirrhotic patient presents with delirium but has a normal ammonia level, clinicians should investigate alternative etiologies because a normal result has a high negative predictive value for hepatic encephalopathy. 10
• In the absence of liver disease—particularly in neonates, infants, or patients on valproic acid—evaluation for inherited metabolic disorders or drug toxicity is warranted. [8][9]
• Routine ammonia measurement in established cirrhotic patients with hepatic encephalopathy is not recommended, as guidelines cite low sensitivity, low specificity, and minimal impact on management decisions. 10

Hyperammonemia in Liver Cirrhosis: Mechanisms, Metabolic Consequences, and Clinical Management

Mechanisms of Ammonia Accumulation

• In liver cirrhosis, elevated ammonia arises from (1) impaired hepatic clearance due to loss of functional liver tissue and (2) increased portosystemic shunting that bypasses the urea cycle, together with heightened ammonia production from the gut and kidneys. 11
• The liver’s normal conversion of ammonia to urea via the urea cycle is markedly reduced in cirrhosis because of loss of metabolic capacity, directly decreasing ammonia detoxification. 11
• Portosystemic shunting—whether surgical (e.g., TIPSS) or spontaneous collaterals—allows ammonia‑rich portal blood to bypass the liver and enter systemic circulation. 11
• Skeletal muscle normally acts as an auxiliary ammonia‑detoxifying organ through glutamine synthesis, but this compensatory pathway becomes overwhelmed in cirrhosis. 11

Metabolic Derangements Contributing to Hyperammonemia

• Cirrhosis leads to reduced circulating branched‑chain amino acids (BCAAs), which are essential for glutamine synthesis and extra‑hepatic ammonia detoxification. 11
• BCAA depletion accelerates muscle protein breakdown and impairs the body’s capacity to handle ammonia. 11
• The altered protein metabolism creates an “accelerated starvation” state characterized by increased whole‑body protein catabolism. 11
• Zinc functions as a cofactor in the urea cycle; zinc deficiency in cirrhosis is linked to hepatic encephalopathy, frailty, and sarcopenia. 11

Direct Toxic Effects of Ammonia

• Ammonia exerts direct myotoxicity by decreasing protein synthesis, increasing autophagy and proteolysis, and causing mitochondrial oxidative dysfunction. 11
• Post‑translational modifications of contractile proteins coupled with bioenergetic dysfunction lead to muscle contractile impairment and loss of muscle mass. 11
• Ammonia plays a central role in hepatic encephalopathy pathophysiology through complex interactions with systemic inflammation and neuroinflammatory processes. 12

Clinical Diagnostic Recommendations

• A normal blood ammonia level in a cirrhotic patient presenting with delirium has a high negative predictive value and should prompt evaluation for alternative causes of encephalopathy. 12
• Blood ammonia concentrations correlate with hepatic encephalopathy (HE) severity; however, hyperammonemia can be present without overt HE, and ammonia may remain elevated after clinical resolution. 12
• The European Association for the Study of the Liver (EASL) guidelines recommend measuring ammonia in patients with delirium and liver disease specifically to rule out HE when the level is normal. 12

Etiology‑Specific Variations in Sarcopenia

• Alcohol‑associated liver disease is associated with a particularly high prevalence of sarcopenia (≈ 80 % in decompensated cirrhosis) due to additive effects of alcohol on muscle autophagy and proteasome inhibition. 11
• Non‑alcoholic steatohepatitis (NASH)‑related cirrhosis carries an increased risk of sarcopenia driven by insulin resistance and chronic systemic inflammation. 11

Muscle Wasting Beyond Malnutrition

• Muscle wasting in cirrhosis is not solely a consequence of inadequate nutrition; ammonia directly induces myotoxic effects via specific molecular pathways. 11